Evidence map›Paper›PMID 38745196›Full record

ReviewJournal of hematology & oncology2024

Critical role of the gut microbiota in immune responses and cancer immunotherapy.

Zehua Li, Weixi Xiong, Zhu Liang, Jinyu Wang, Ziyi Zeng, Damian Kołat, Xi Li, Dong Zhou, Xuewen Xu, Linyong Zhao

Abstract readReview
In one paragraph

Review in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Microbiome-guided cancer immunotherapy: immune mechanisms, resistance pathways, and translational opportunities for precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Review
  19. Article
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zehua Li *Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu, China.
Weixi Xiong *Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Zhu Liang *Chinese Academy of Medical Sciences (CAMS), CAMS Oxford Institute (COI), Nuffield Department of Medicine, University of Oxford, Oxford, England.
Jinyu WangDepartments of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China.
Ziyi ZengDepartment of Neonatology, West China Second University Hospital of Sichuan University, Chengdu, China.
Damian KołatDepartment of Functional Genomics, Medical University of Lodz, Lodz, Poland.
Xi LiDepartment of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation, Oxford, UK.
Dong ZhouDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Xuewen XuDepartment of Plastic and Burn Surgery, West China Hospital, Sichuan University, Chengdu, China.
Linyong ZhaoDepartment of General Surgery and Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China. 153795352@scu.edu.cn.

Funding

National Natural Science Foundation of China No.82102998
6 · The paper itself

Abstract

The gut microbiota plays a critical role in the progression of human diseases, especially cancer. In recent decades, there has been accumulating evidence of the connections between the gut microbiota and cancer immunotherapy. Therefore, understanding the functional role of the gut microbiota in regulating immune responses to cancer immunotherapy is crucial for developing precision medicine. In this review, we extract insights from state-of-the-art research to decipher the complicated crosstalk among the gut microbiota, the systemic immune system, and immunotherapy in the context of cancer. Additionally, as the gut microbiota can account for immune-related adverse events, we discuss potential interventions to minimize these adverse effects and discuss the clinical application of five microbiota-targeted strategies that precisely increase the efficacy of cancer immunotherapy. Finally, as the gut microbiota holds promising potential as a target for precision cancer immunotherapeutics, we summarize current challenges and provide a general outlook on future directions in this field.

Indexed as

Gastrointestinal MicrobiomeImmunotherapyNeoplasmsAnimalsHumansCancer immunotherapyGut microbiota-derived metabolitesImmune checkpoint inhibitorsImmune-related adverse eventsMicrobiota modification

Identifiers

PMID38745196
PMCPMC11094969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.